10:34 AM EDT, 08/04/2025 (MT Newswires) -- (Updates with recent share price movement in the headline and first paragraph and analyst expectations for full-year revenue in the final paragraph.)

TG Therapeutics ( TGTX ) shares were down over 16% in recent Monday trading after the company reported Q2 earnings that increased year-over-year but fell short of analyst expectations.

The company reported Q2 net income of $0.17 per diluted share, up from $0.04 a year earlier.

Analysts polled by FactSet expected $0.21.

Revenue for the quarter ended June 30 was $141.1 million, compared with $73.5 million a year earlier.

Analysts surveyed by FactSet expected $138 million.

For 2025, the company now expects global revenue of $585 million, compared with its prior guidance of $575 million.

Analysts polled by FactSet expect full-year revenue of $578.5 million.

Price: 29.15, Change: -5.87, Percent Change: -16.77